160 related articles for article (PubMed ID: 33976086)
1. Markers of Bile Acid Metabolism in Pediatric Diarrhea Predominant Irritable Bowel Syndrome and Healthy Controls.
Beinvogl BC; Manini ML; Camilleri M; Donato LJ; Harmsen WS; Absah I; Burch E; Schechter NL; Nurko S
J Pediatr Gastroenterol Nutr; 2021 Jun; 72(6):859-865. PubMed ID: 33976086
[TBL] [Abstract][Full Text] [Related]
2. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea.
Wong BS; Camilleri M; Carlson P; McKinzie S; Busciglio I; Bondar O; Dyer RB; Lamsam J; Zinsmeister AR
Clin Gastroenterol Hepatol; 2012 Sep; 10(9):1009-15.e3. PubMed ID: 22610000
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for Bile Acid Malabsorption in Diarrhea-predominant Irritable Bowel Syndrome: A Systematic Review and Meta-analysis.
Liu T; Ma M; Li K; Tan W; Yu H; Wang L
J Clin Gastroenterol; 2023 May-Jun 01; 57(5):451-458. PubMed ID: 36867517
[TBL] [Abstract][Full Text] [Related]
4. Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples.
Vijayvargiya P; Busciglio I; Burton D; Donato L; Lueke A; Camilleri M
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):522-527. PubMed ID: 28666948
[TBL] [Abstract][Full Text] [Related]
5. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea.
Camilleri M; Busciglio I; Acosta A; Shin A; Carlson P; Burton D; Ryks M; Rhoten D; Lamsam J; Lueke A; Donato LJ; Zinsmeister AR
Am J Gastroenterol; 2014 Oct; 109(10):1621-30. PubMed ID: 25070056
[TBL] [Abstract][Full Text] [Related]
6. Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption.
Peleman C; Camilleri M; Busciglio I; Burton D; Donato L; Zinsmeister AR
Clin Gastroenterol Hepatol; 2017 May; 15(5):720-727.e1. PubMed ID: 27856362
[TBL] [Abstract][Full Text] [Related]
7. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome.
Dior M; Delagrèverie H; Duboc H; Jouet P; Coffin B; Brot L; Humbert L; Trugnan G; Seksik P; Sokol H; Rainteau D; Sabate JM
Neurogastroenterol Motil; 2016 Sep; 28(9):1330-40. PubMed ID: 27060367
[TBL] [Abstract][Full Text] [Related]
8. Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome.
Vijayvargiya P; Camilleri M; Burton D; Busciglio I; Lueke A; Donato LJ
Aliment Pharmacol Ther; 2019 Mar; 49(6):744-758. PubMed ID: 30740753
[TBL] [Abstract][Full Text] [Related]
9. Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea.
Vijayvargiya P; Camilleri M; Carlson P; Lueke A; O'Neill J; Burton D; Busciglio I; Donato L
Aliment Pharmacol Ther; 2017 Sep; 46(6):581-588. PubMed ID: 28691284
[TBL] [Abstract][Full Text] [Related]
10. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome.
Wei W; Wang HF; Zhang Y; Zhang YL; Niu BY; Yao SK
World J Gastroenterol; 2020 Dec; 26(45):7153-7172. PubMed ID: 33362374
[TBL] [Abstract][Full Text] [Related]
11. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome.
Shin A; Camilleri M; Vijayvargiya P; Busciglio I; Burton D; Ryks M; Rhoten D; Lueke A; Saenger A; Girtman A; Zinsmeister AR
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1270-1275.e1. PubMed ID: 23639599
[TBL] [Abstract][Full Text] [Related]
12. Validating biomarkers of treatable mechanisms in irritable bowel syndrome.
Camilleri M; Shin A; Busciglio I; Carlson P; Acosta A; Bharucha AE; Burton D; Lamsam J; Lueke A; Donato LJ; Zinsmeister AR
Neurogastroenterol Motil; 2014 Dec; 26(12):1677-85. PubMed ID: 25244349
[TBL] [Abstract][Full Text] [Related]
13. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.
Camilleri M; Acosta A; Busciglio I; Boldingh A; Dyer RB; Zinsmeister AR; Lueke A; Gray A; Donato LJ
Aliment Pharmacol Ther; 2015 Mar; 41(5):438-48. PubMed ID: 25594801
[TBL] [Abstract][Full Text] [Related]
14. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome.
Zhao L; Yang W; Chen Y; Huang F; Lu L; Lin C; Huang T; Ning Z; Zhai L; Zhong LL; Lam W; Yang Z; Zhang X; Cheng C; Han L; Qiu Q; Shang X; Huang R; Xiao H; Ren Z; Chen D; Sun S; El-Nezami H; Cai Z; Lu A; Fang X; Jia W; Bian Z
J Clin Invest; 2020 Jan; 130(1):438-450. PubMed ID: 31815740
[TBL] [Abstract][Full Text] [Related]
15. Impact of Bile Acid Diarrhea in Patients With Diarrhea-Predominant Irritable Bowel Syndrome on Symptoms and Quality of Life.
BouSaba J; Sannaa W; McKinzie S; Vijayvargiya P; Chedid V; Wang XJ; Atieh J; Zheng T; Brandler J; Taylor AL; Busciglio I; Harmsen WS; Camilleri M
Clin Gastroenterol Hepatol; 2022 Sep; 20(9):2083-2090.e1. PubMed ID: 34871814
[TBL] [Abstract][Full Text] [Related]
16. Bile Acid diarrhea: prevalence, pathogenesis, and therapy.
Camilleri M
Gut Liver; 2015 May; 9(3):332-9. PubMed ID: 25918262
[TBL] [Abstract][Full Text] [Related]
17. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.
Duboc H; Rainteau D; Rajca S; Humbert L; Farabos D; Maubert M; Grondin V; Jouet P; Bouhassira D; Seksik P; Sokol H; Coffin B; Sabaté JM
Neurogastroenterol Motil; 2012 Jun; 24(6):513-20, e246-7. PubMed ID: 22356587
[TBL] [Abstract][Full Text] [Related]
18. Serum Levels of Fibroblast Growth Factor 19 Correlate with the Severity of Diarrhea and Independently from Intestinal Inflammation in Patients with Inflammatory Bowel Disease or Microscopic Colitis.
Lyutakov I; Nakov R; Valkov H; Vatcheva-Dobrevska R; Vladimirov B; Penchev P
Turk J Gastroenterol; 2021 Apr; 32(4):374-381. PubMed ID: 34231484
[TBL] [Abstract][Full Text] [Related]
19. Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial.
Vijayvargiya P; Camilleri M; Carlson P; Nair A; Nord SL; Ryks M; Rhoten D; Burton D; Busciglio I; Lueke A; Harmsen WS; Donato LJ
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2962-2970.e6. PubMed ID: 32088296
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome-Diarrhea With or Without Bile Acid Diarrhea: Open-Label Study.
Vijayvargiya P; Breen-Lyles M; Nord SL; Maselli D; Busciglio I; Boinpally R; Muslin A; Carrothers TJ; Camilleri M
Dig Dis Sci; 2022 Aug; 67(8):3911-3921. PubMed ID: 35122592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
